arrow_back Back to App

Pandemic Emergency Manufacturing Act: Boosting Access to Medicines and Equipment

This act establishes a new office within the Department of Health to ensure a steady supply of medicines, vaccines, and protective equipment, especially during pandemics. Its goal is to prevent shortages and reduce costs, directly impacting healthcare accessibility and public safety.
Key points
A new government office will be created to manufacture or contract for the production of drugs, vaccines, and medical devices to prevent shortages.
COVID-19 related products will be provided free of charge to health programs and at cost to other entities, potentially lowering prices.
The office will ensure fair and accessible drug prices for patients, considering production costs and market competition.
The act prohibits the employment of former pharmaceutical lobbyists and executives from law-breaking companies to ensure the office's integrity.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_187
Sponsor: Sen. Warren, Elizabeth [D-MA]
Process start date: 2021-02-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pandemic Emergency Manufacturing Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_187.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-03.

What are the main provisions?

Key points include:

  • A new government office will be created to manufacture or contract for the production of drugs, vaccines, and medical devices to prevent shortages.
  • COVID-19 related products will be provided free of charge to health programs and at cost to other entities, potentially lowering prices.
  • The office will ensure fair and accessible drug prices for patients, considering production costs and market competition.
  • The act prohibits the employment of former pharmaceutical lobbyists and executives from law-breaking companies to ensure the office's integrity.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Warren, Elizabeth [D-MA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Public Investments